This site is for health care professionals only.

@ ESMO Virtual Congress 2020

 

Reimagining Lung Cancer: Discover Pro-Tumor Inflammation and Understand MET Mutations

Lung Cancer Disease Education Library

watering a tumor next to sign that reads Please Don’t Feed The Tumor

Pro-Tumor Inflammation

Learn More

sign with arrow directing to MET NSCLC

Understanding MET in NSCLC

Clinical Trials

CANOPY-A
Capmatinib + Spartalizumab vs Docetaxel in Locally Advanced or Metastatic NSCLC
Capmatinib Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC with PD-L1 ≥ 50%
Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients with MET Exon 14 Skipping Mutations

Compound Cards

IL-1β antibody: Canakinumab (ACZ885)
MET inhibitor: Capmatinib (INC280)
PD-1 monoclonal antibody: Spartalizumab (PDR001)
All compounds are either investigational or being studied for (a) new uses(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.